TVM is a leading international venture capital firm focused on investing in life science innovations. The company has a highly experienced transatlantic investment team and approximately $900 million under management. TVM’s portfolio focuses on therapeutics and medical technologies from North America and the EU that represent differentiated first-in-class or best-in-class assets with the potential to transform standard of care.

TVM pursues a unique two-pronged strategy, financing innovative early-stage therapeutics through a single asset company approach (Project-Focused Company, PFC) that leverages the firm’s strategic relationship with global pharmaceutical firm, Eli Lilly and Company. TVM also invests in differentiated commercial-stage medical technologies and late clinical-stage therapeutics.

The TVM investment team has worked together for over a decade to effectively utilize this innovative approach to maximize returns for investors and finance new therapies and technologies to meaningfully improve patient lives.

Biotechnology

Health Care

Medical Devices

Pharmaceutical

Therapeutics

Venture Capital

TVM Capital Life Science

Luc Marengère

Dominique Larose

Marc Rivière

Ivan Shaw

Jijimon Augustine

Sascha Berger

Josef Moosholzer

Valentina Agostoni

Tanja Takides

Philipp Lechner

Munich Team

Montreal Team

Barbara Hauser

Hubert Birner

Hoffmann - La Roche

Investment Team

Finance and Accounting

Leadership Team

Teams at TVM Capital Life Science

Investment Team

Finance and Accounting

Leadership Team